Chanchal Chandramouli

Wrapped the final investigator meeting for the ADOPT trial in Singapore! 🚀Grateful to our investigators, leads, coordinators & partners—what a 5-year journey of grit, growth & global teamwork. 18 months to go till home-run! Let’s finish strong! 📷 #ADOPTtrial

📺 Catch my husband on Mediacorp’s Pesuvom this Tue, 18 Nov at 9.30pm on Vasantham as he breaks down prostate cancer with clarity, compassion, and the calm of someone who answers 200 patient questions before lunch. 👨‍⚕️✨ #ProstateCancer #MensHealth

🎥 Honored to join the APSC Webinar panel alongside inspiring colleagues discussing cardio-kidney-metabolic care in Asia 📷Such vibrant community driving cardiovascular science forward📷 Watch the full session: youtu.be/j-OXnHWzKQI?t=… #APSC #CardioRenalMetabolic #HeartFailure

Congratulations @lamcardio on the NMEA Clinician Scientist Award. Super proud to have been on the journey with you, in a small way. Thanks @SingHealthSG for the opportunity for us to conduct trials worldwide in an impactful way 🙏

ALCHEMIST & ACHIEVE in @TheLancet this week Spironolactone does not reduce cardiovascular morbidity / mortality in hemodialysis patients Huge congrats to Mike Walsh, Patrick Rossignol & all involved thelancet.com/journals/lance… thelancet.com/journals/lance…

📢 New Research from @CKMResearch @KPDOR @ankeetbhatt "Cardiovascular-Kidney-Metabolic Syndrome: A Paradigm for Value-Based Care" proposes an integrated model to tackle urgent & costly health crisis in the U.S. 🔗 Read: onlinejcfi.org/article/S3050-… #ValueBasedCare #CKM #HealthEquity

Midway through an amazing robotic fellowship at the @enherts Lister hospital with @nikhilvasdevuro @MrTimLane @jimadshead Mr Ben Pullar and Mr Andy Brodie. Is has been an immense 7 months so far with my co-fellow and obligate friends for life @MrRossWarner

Honoured to be joining this stellar line up of Lancet Commissioners for the next two years under the leadership of @lamcardio and @ProfSNicholls 🫀🫶🏼 Many voices, singular message - To reduce CVD burden in Asia-Pacific 🚀 #ESCcongress2024 #Lancet

Women on editorial boards: where are they? 📍26 EIC from 49 journals 📍20% women EIC 2023 🆚 5% 2013 📍 ⤴️26% women on editorial boards in 2023 (19% in 2013) 📍more women if EIC woman 📍why so few 💃🏻? Less WIC but also they state 💃🏻 “under qualified” 📎 rb.gy/2iytjy

Asymptomatic patients with type 2 diabetes and no heart failure: 🍿44% with cardiac abnormalities with NO elevation in NT-proBNP levels 🍿5% with elevated NT-proBNP and no cardiac abnormalities 🍿15% with BOTH elevated NT-proBNP AND cardiac abnormalities. #ESCCongress2024

#ESCCongressVisuals for Hotline 7: FINEARTS-HF - #Finerenone in #HeartFailure with mildly reduced and preserved ejection fraction MRAs in #HF - An individual patient data meta-analysis of randomised trials FINE-HEART - Participant-level pooled analysis of finerenone in heart failure and chronic kidney disease trials #ESCCongress

@__YmH_ @escardio Hi @__YmH_ !

@chanchal5688 @escardio Hello @chanchal5688 ☺️

A mini ADOPT reunion at @escardio #ESCCongress2024 who else is here? Come say hello!

Implementing Medical Therapy During Worsening #HeartFailure released at #ESCCongress and just published in #EHJ👉 bit.ly/4cMFoUg @ehj_ed @ankeetbhatt

#Sex, #race, and #BMI in clinical trials of medications for #obesity over the past three decades: a systematic review thelancet.com/journals/landi… #obesity

Great catching up with @DianaFooMD and @BCstyling at #ESCCongress2024

Original Article: Beta-Blocker Interruption or Continuation after Myocardial Infarction (ABYSS) nej.md/3MeRHOi Editorial: Routine Beta-Blockers in Secondary Prevention — Approaching Retirement? nej.md/3Me7EnW #ESCardio | @escardio

📝New #OriginalResearch published in #CircOutcomes from @lamcardio et al: Discordance between #KCCQ score and #NYHA class was common in HF and related to outcomes in #HFrEF and #HFpEF. Read more: ahajournals.org/doi/abs/10.116… #AHAJournals @chanchal5688 @Claire_A_Lawson

What do you think is the most important factor in ensuring patients' positive attitude towards AI technology? Performance? Ease of use? Social influence? Resources to support? Or the sheer fun of it? 💡We think it is ALL of the above! Hot off the press: #Fig1" target="_blank" rel="nofollow noopener">bmchealthservres.biomedcentral.com/articles/10.11…